Publicaciones en colaboración con investigadoras/es de Eli Lilly and Company (19)

2022

  1. Longitudinal clinical and biomarker characteristics of non-manifesting LRRK2 G2019S carriers in the PPMI cohort

    npj Parkinson's Disease, Vol. 8, Núm. 1

2019

  1. Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI)

    Parkinsonism and Related Disorders, Vol. 62, pp. 201-209

2018

  1. The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort

    Annals of Clinical and Translational Neurology, Vol. 5, Núm. 12, pp. 1460-1477

2011

  1. 2-year course of bipolar disorder type I patients in outpatient care: Factors associated with remission and functional recovery

    European Neuropsychopharmacology, Vol. 21, Núm. 4, pp. 287-293

  2. Effectiveness of olanzapine monotherapy and olanzapine combination treatment in the long term following acute mania - Results of a two year observational study in bipolar disorder (EMBLEM)

    Journal of Affective Disorders, Vol. 131, Núm. 1-3, pp. 320-329

  3. Gender differences in outcomes of acute mania: A 12-month follow-up study

    Archives of Women's Mental Health, Vol. 14, Núm. 2, pp. 107-113

2010

  1. Assessment of medication adherence in a cohort of patients with bipolar disorder

    Pharmacopsychiatry, Vol. 43, Núm. 7, pp. 263-270

  2. Baseline characteristics and outcomes in patients with first episode or multiple episodes of acute mania

    Journal of Clinical Psychiatry, Vol. 71, Núm. 3, pp. 255-261

  3. Comparison of olanzapine and risperidone in the EMBLEM Study: Translation of randomized controlled trial findings into clinical practice

    International Clinical Psychopharmacology, Vol. 25, Núm. 5, pp. 257-263

2009

  1. Observational study designs for bipolar disorder - What can they tell us about treatment in acute mania?

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 33, Núm. 4, pp. 715-721

  2. Translation of randomised controlled trial findings into clinical practice: Comparison of olanzapine and valproate in the EMBLEM study

    Pharmacopsychiatry, Vol. 42, Núm. 4, pp. 145-152

  3. Validity and reliability of the Hamilton Depression Rating Scale (5 items) for manic and mixed bipolar disorders

    Journal of Nervous and Mental Disease, Vol. 197, Núm. 9, pp. 682-686

2007

  1. Effect of comorbid anxiety on treatment response in bipolar depression

    Journal of Affective Disorders, Vol. 104, Núm. 1-3, pp. 137-146

  2. Functional impairment in patients with mania: Baseline results of the EMBLEM study

    Bipolar Disorders, Vol. 9, Núm. 1-2, pp. 45-52

  3. Outcomes for Latin American versus white patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol

    Journal of Clinical Psychopharmacology, Vol. 27, Núm. 2, pp. 126-134

  4. Patterns of drug treatment for manic episode in the clinical practice. Outcomes of the Spanish sample in the EMBLEM Study

    Actas Espanolas de Psiquiatria, Vol. 35, Núm. 5, pp. 315-322

2006

  1. Quality of life and social functioning in schizophrenic patients treated with olanzapine: 1 Year follow-up naturalistic study

    Actas Espanolas de Psiquiatria, Vol. 34, Núm. 1, pp. 7-15

2003

  1. A 12-Week, Double-blind Comparison of Olanzapine vs Haloperidol in the Treatment of Acute Mania

    Archives of General Psychiatry, Vol. 60, Núm. 12, pp. 1218-1226

2001

  1. Use of olanzapine in dysphoric mania

    Journal of Affective Disorders, Vol. 66, Núm. 2-3, pp. 247-253